Comment from Center on Reproductive Health, Law, and Policy

Summary: The UCLA Law Center for Reproductive Health, Law, and Policy and UCSF Advancing New Standards in Reproductive Health, representing 263 researchers, support the citizen petitions asking the FDA to refrain from imposing additional restrictions on mifepristone. They argue that decades of gold-standard science confirm the safety and effectiveness of the medication, while criticizing recent reports from the Ethics and Public Policy Center as methodologically flawed and non-reproducible.